Yuchen Wang

Yuchen Wang

Auto-generated profile, based on publicly available information

Yuchen Wang

Department of Internal Medicine, John H. Stroger Hospital of Cook County, Chicago, IL

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Pancreatology
Verified
Journal Article
Closed access
YWYuchen Wang
Yuchen Wang
HFHarry Fuentes-Bayne
Harry Fuentes-Bayne
BABashar M. Attar
Bashar M. Attar
PJPalash Jaiswal
Palash Jaiswal
MDMelchor Demetria
Melchor Demetria

14 March 2017 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
YWY. Wang
Y. Wang
BAB. M. Attar
B. M. Attar
HFH. E. Fuentes
H. E. Fuentes
JYJ. Yu
J. Yu
HZHuiyuan Zhang
Huiyuan Zhang
ATA. J. Tafur
A. J. Tafur
Cancer-associated venous thromboembolism (VTE) is one of the leading causes of mortality and morbidity among patients with malignancy. The Khorana risk score (KRS) is currently the best validated risk assessment model to stratify risks of VTE development in ambulatory patients with cancer. In the current study, we assessed the performance of KRS in patients with hepatocellular carcinoma (HCC). We retrospectively analyzed patients with diagnosis of HCC (screened by International Classification of Diseases [ICD-9] and ICD-10 code, confirmed with radiographic examination and/or histopathology) at a large public hospital over 15 years (January 2000 through July 2015). Cases with VTE were identified through radiographic examination and blindly adjudicated. Khorana risk score was calculated for each patient, and its association with VTE development and mortality was assessed. Among 270 patients with HCC, 16 (5.9%) cases of VTE were identified, including 7 (43.8%) pulmonary embolism, 4 (25%) peripheral deep vein thrombosis, and 6 (37.5%) intra-abdominal thrombosis. One hundred eighty-four (68.1%) patients had a KRS of 0 and 86 (31.9%) patients had a KRS >0. Most of the thrombotic (n = 9, 56%) events occurred in the low-risk group. In univariate analysis, only prechemotherapy leukocyte count equal to or greater than 11 000/μL was statistically significant in the prediction of VTE incidence. After adjusting for confounding factors in multivariate analysis, KRS >0 was not predictive of VTE (hazard ratio [HR] = 1.83, 95% confidence interval [CI] = 0.81-4.15, P = .15) or mortality (HR = 1.61, 95% CI = 0.92-2.81, P = .09). Khorana risk score did not predict VTE development or mortality in patients with HCC. Design of HCC-specific risk assessment model for VTE development is necessary.

1 December 2017 in Journal of Gastrointestinal Oncology
Verified
Journal Article
Closed access
PDF file
YWYuchen Wang
Yuchen Wang
BABashar M. Attar
Bashar M. Attar
HFHarry E. Fuentes
Harry E. Fuentes
PJPalashkumar Jaiswal
Palashkumar Jaiswal
ATAlfonso J. Tafur
Alfonso J. Tafur
Background: Hepatocellular carcinoma (HCC) is increasingly common, potentially fatal cancer type globally. Platelet-lymphocyte ratio (PLR) as a biomarker for systemic inflammation has recently been recognized as a valuable prognostic marker in multiple cancer types. The aim of the present study was to assess the prognostic value of PLR in HCC patients and determine the optimal cut-off value for risk stratification. Methods: We retrospectively analyzed patients with diagnosis of HCC (screened by ICD-9 code, confirmed with radiographic examination and/or biopsy) at a large public hospital during 15 years (Jan 2000 through July 2015). PLR, among other serology laboratory values were collected at diagnosis of HCC. Its association with overall survival was evaluated with Cox proportional hazard model. Results: Among 270 patients with HCC, 57 (21.1%) patients died within an average follow-up of 11.9 months. PLR at diagnosis was significantly different between survivors and deceased (128.9 vs. 186.7; P=0.003). In multivariate analysis, aspartate transaminase (AST) (HR 2.022, P<0.001) and PLR (HR 1.768, P=0.004) independently predicted mortality. The optimal cut-off value for PLR was determined to be 220 by receiver-operating characteristics curve, and high PLR group had significantly higher mortality (HR 3.42, P<0.001). Conclusions: Our results indicated that elevated PLR at diagnosis above 220 predicted poor prognosis in HCC patients. PLR is a low-cost and convenient tool, which may serve as a useful prognostic marker for HCC.

30 October 2024 in Phytomedicine
Verified
Journal Article
Closed access
DYDi Yang
Di Yang
GLGuangfu Lv
Guangfu Lv
YWYongxi Wu
Yongxi Wu
WGWentao Guo
Wentao Guo
YWYuchen Wang
Yuchen Wang
HYHao Yue
Hao Yue

13 November 2019 in Cureus
Verified
Journal Article
Open access
PDF file
YOYazan Abu Omar
Yazan Abu Omar
TRTejinder Randhawa
Tejinder Randhawa
BABashar Attar
Bashar Attar
RARohit Agrawal
Rohit Agrawal
YWYuchen Wang
Yuchen Wang
SPSanjay Patel
Sanjay Patel
Prednisolone is considered the cornerstone treatment for severe alcoholic hepatitis (AH). However, its use is limited by the increased risk of infection in an already immunocompromised patient population. Among patients with severe AH, there exists a group of non-responders who do not benefit from prednisolone therapy. Day-4 Lille score is a widely employed prognostic model used to identify this non-responder subgroup. The present study evaluates the prognostic ability of the inflammatory marker, the neutrophil-lymphocyte ratio (NLR), as a stand-alone model and in conjunction with the day-4 Lille score. We retrospectively reviewed the electronic medical records of patients diagnosed with AH. Demographic and biochemical data at diagnosis were collected to calculate Maddrey’s discriminant function (MDF) and model for end-stage liver disease (MELD) score upon admission and also on day 4. Receiver operating characteristic (ROC) curves were plotted for day-4 NLR and day-4 Lille score for prediction of 90-day mortality, and optimal cut-off values were determined. Patients were then subcategorized into groups based on the generated optimal cut-off values. Categorization was validated by comparing the mortality rate in each group with the chi-squared test. We then performed a multivariate analysis for prediction of 90-day mortality using day-4 Lille score and day-4 NLR, constructing a new prediction score based on the odds ratio (OR). The ROC curve of the new score was plotted and the area under a curve (AUC) was reported and compared with previously validated scores. Our analysis demonstrated that both day-4 NLR and Lille score individually predicted 90-day mortality with statistical significance (p: 0.049, p: <0.001, respectively). The ROC analysis of day-4 Lille score for the prediction of 90-day mortality revealed an AUC of 0.819 with an optimal cut-off value of 0.45 (sensitivity: 83.3%, specificity: 76.1%). Day-4 NLR had an AUC of 0.756 with an optimal cut-off value of 12.3 (sensitivity: 66.7%, specificity: 78.1%) The combined day-Lille-NLR model with a cut-off of 0.55 had an AUC of .889, which was higher than day-4 Lille score and NLR independently. Day-4 NLR is an easily assessed prognostic model of mortality in alcoholic hepatitis. However, it often underperforms relative to day-4 Lille score. Combining these two models to create a "modified" Lille score adds increased performance characteristics to the prediction of outcomes/mortality. The "modified" Lille score presented in this study can be used to further cut down the number of non-responders who are often forced to undergo costly and potentially harmful treatment courses.

4 April 2017 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Closed access
PDF file
YWYuchen Wang
Yuchen Wang
BAB. M. Attar
B. M. Attar
KHK. Hinami
K. Hinami
HFH. E. Fuentes
H. E. Fuentes
PJP. Jaiswal
P. Jaiswal
ATA. J. Tafur
A. J. Tafur